About
Drug delivery technology platform, half-life extension
Areas of Focus
Categories
Drug Delivery & FormulationBiotech
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
1
As Collaborator
3
Total Enrollment
189
By Phase
PHASE1: 3PHASE2: 1
By Status
RECRUITING: 3COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06894745Collaborator
PET [89Zr]DFO-starPEG in Solid Tumors
PHASE1Recruiting
13 participants
Started: Jun 2, 2025 · Completed: Dec 31, 2027
NCT06337630Collaborator
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
PHASE1Recruiting
92 participants
Started: Jan 20, 2025 · Completed: Sep 23, 2029
NCT06162351Collaborator
A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer
PHASE2Recruiting
44 participants
Started: Apr 17, 2024 · Completed: Apr 17, 2027
NCT02646852Lead Sponsor
A Phase I Study of PLX038 in Patients With Advanced Solid Tumors
PHASE1Completed
40 participants
Started: Mar 31, 2016 · Completed: Jul 31, 2023
Funding History (1)
D
Sep 10, 2020
Locations (1)
Headquarters
San Francisco, CA, United States
Map
Loading map...